Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgery plus GP chemotherapy and targeted immunotherapy for locally recurrent nasopharyngeal carcinoma
ChiCTR2600124353Phase 2Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: progression-free survival. Started May 2026; status: recruiting.
02
Drugs
gemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2600124353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124353.